Overview

Gender

male

Satyavrat “Sath” Shukla, CFA, joined Ziopharm as Chief Financial Officer in July 2019 to direct all financial planning, analysis and reporting, treasury and tax functions, and take on a key leadership role in the company’s capital strategy development and investor relations activities. With 20 years of strategic corporate and financial leadership experience, Sath was most recently VP and global Head of Corporate Finance for Vertex Pharmaceuticals, where he managed financial planning, analysis and budgeting, and led the annual long-range planning process encompassing Vertex’s entire portfolio and operations across more than 30 countries. Previously, Mr. Shukla was a Principal at Cornerstone Research, where he led teams providing consulting services for life science clients ranging from start-ups to multi-billion-dollar corporations. Prior to Cornerstone, he worked for finance consulting firms LECG and Putnam, Hayes & Bartlett. Mr. Shukla earned a BA in Economics from Harvard University and an MBA in Finance and Strategy from Yale University.